All In Biotech

Drug Trial Radar · NCT04869501

Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer

Expanded Access Protocol for an Intermediate Size Population-use of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer

Last checked: Nov 19, 2026Latest source record: Apr 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

No longer available

Status

No longer available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
I-Mab Biopharma US LimitedIndustry
Sponsor type
Industry
First posted
May 3, 2021

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes

Summary

As written by the sponsor on the registry.

This expanded access protocol was designed to provide TJ004309 in combination with atezolizumab to the remaining three patients with advanced or metastatic cancer who plan to continue with treatment.

Conditions

  • Cancer

Interventions

  • TJ004309Drug

    Antibody to CD73

  • AtezolizumabDrug

    Humanized monoclonal antibody to PD-L1

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • Arizona Oncology Associates, P.C.

    Tucson, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.